Survey highlights success criteria for EU drug approval applications
This article was originally published in Scrip
Those companies most likely to get a new drug approved by the European Medicines Agency (EMA) tend to be larger firms with more resources and more experience in drug development and approval applications, and which have made full use of the scientific advice offered by the agency.
You may also be interested in...
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
The recruitment process for the new executive director of the European Medicines Agency seems to be running to schedule.
Russia’s new drug traceability system won’t now be implemented until July, but companies that are ready and able are being encouraged to put the system through its paces in order to flush out any glitches.